Esperance Pharmaceuticals is a clinical‑stage company developing a new class of targeted anticancer drugs using its patented Cationic Lytic Peptide (CLYP™) platform. Its lead candidate, EP‑100, is designed to seek and destroy cancer cells that over‑express luteinizing hormone releasing hormone (LHRH) receptors and is currently in a Phase 1 study in patients with advanced solid tumors. The company plans to use the new capital to advance studies of EP‑100 and to continue expanding its product pipeline. Esperance was built on technology discovered by scientists at the Pennington Biomedical Research Center, the LSU Ag Center and LSU main campus. The company is led by President and CEO Hector Alila, PhD, and is based in Baton Rouge, Louisiana.

Total raised

$8M

Funding rounds

1

Latest round

Series B

Latest activity

Jun 2011